For the love of paradox: from neurobiology to pharmacology.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 3155657)

Published in Behav Pharmacol on September 01, 2011

Authors

Richard A Bond1, Heather Giles

Author Affiliations

1: Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston, Texas 77204-5037, USA. RABond@UH.Edu

Articles cited by this

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 8.43

beta-adrenergic receptor blockade in chronic heart failure. Circulation (2000) 3.43

Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation (1998) 2.35

Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol (2007) 2.24

Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci U S A (2004) 1.85

The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther (2007) 1.61

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol (1995) 1.55

Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A (2009) 1.53

New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma. Br J Pharmacol (2011) 1.46

Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation (1995) 1.40

Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther (2007) 1.30

Is paradoxical pharmacology a strategy worth pursuing? Trends Pharmacol Sci (2001) 1.21

Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J (2010) 1.07

Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant? Curr Opin Pharmacol (2007) 1.01

5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief. Curr Opin Investig Drugs (2006) 0.99

Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis. Reprod Biol Endocrinol (2010) 0.96

Getting to the heart of asthma: can "beta blockers" be useful to treat asthma? Pharmacol Ther (2007) 0.94

Can intellectualism stifle scientific discovery? Nat Rev Drug Discov (2002) 0.94

Curative-like analgesia in a neuropathic pain model: parametric analysis of the dose and the duration of treatment with a high-efficacy 5-HT(1A) receptor agonist. Eur J Pharmacol (2007) 0.89

Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med (2010) 0.87

Role of spinal 5-HT(1A) receptors in morphine analgesia and tolerance in rats. Eur J Pain (2004) 0.87

Cardiotonic agents in the management of chronic cardiac failure. Am Heart J (1982) 0.86

beta-Adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol (2010) 0.86

Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters. J Pharmacol Exp Ther (2004) 0.83

Emerging gonadotropin-releasing hormone agonists. Expert Opin Emerg Drugs (2011) 0.78